View in EDS

Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.

Saved in:

Bibliographic Details
Title:	Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
Authors:	Liu C; Aligos Therapeutics, Inc., South San Francisco, USA., Boland S; Cistim, Leuven, Belgium., Scholle MD; SAMDI Tech, Inc., Chicago, USA., Bardiot D; Cistim, Leuven, Belgium., Marchand A; Cistim, Leuven, Belgium., Chaltin P; Cistim, Leuven, Belgium; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, USA., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Gurard-Levin ZA; SAMDI Tech, Inc., Chicago, USA., Vandyck K; Aligos Belgium BV, Leuven, Belgium., Deval J; Aligos Therapeutics, Inc., South San Francisco, USA. Electronic address: jdeval@aligos.com.
Source:	Antiviral research [Antiviral Res] 2021 Mar; Vol. 187, pp. 105020. Date of Electronic Publication: 2021 Jan 27.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9096 (Electronic) Linking ISSN: 01663542 NLM ISO Abbreviation: Antiviral Res Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1872-9096
DOI:	10.1016/j.antiviral.2021.105020